Sun Pharma Advanced Research Com Share Price
Sector: Business Services
243.05 +2.90 (1.21%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
238.25
Today’s High
245
52 Week Low
196.45
52 Week High
474
243.03 +2.76 (1.15%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
238.04
Today’s High
245
52 Week Low
196.1
52 Week High
472.8
Key Metrics
- Market Cap (In Cr) 7797.28
- Beta 1.54
- Div. Yield (%) 0
- P/B 62.01
- TTM P/E -
- Sector P/E 31.74
- D/E 0.52
- Open Price 240.15
- Prev Close 240.15
Sun Pharma Advanced Research Com Analysis
Price Analysis
-
1 Week-2.98%
-
3 Months-38.92%
-
6 Month-37.95%
-
YTD-16.22%
-
1 Year16.78%
Risk Meter
- 56% Low risk
- 56% Moderate risk
- 56% Balanced Risk
- 56% High risk
- 56% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 0
- 1
- 1
- 1
- Buy
- 1
- 1
- 1
- 1
- Hold
- 0
- 0
- 0
- 0
- Sell
- 0
- 0
- 0
- 0
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 1
- 2
- 2
- 2
Sun Pharma Advanced Research Com News
Over 45 BSE small-cap stocks surge between 15-50% even as market ends week flat
4 min read . 07 Jan 2024Sun Pharma Advanced Research Com Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 75.55
- Selling/ General/ Admin Expenses Total
- 395.65
- Depreciation/ Amortization
- 12.51
- Other Operating Expenses Total
- 53.87
- Total Operating Expense
- 490.16
- Operating Income
- -414.61
- Net Income Before Taxes
- -386.83
- Net Income
- -387.21
- Diluted Normalized EPS
- -11.93
- Period
- 2024
- Total Assets
- 515.04
- Total Liabilities
- 389.29
- Total Equity
- 125.75
- Tangible Book Valueper Share Common Eq
- 2.56
- Period
- 2024
- Cashfrom Operating Activities
- -429.2
- Cashfrom Investing Activities
- 391.53
- Cashfrom Financing Activities
- 42.42
- Net Changein Cash
- 4.75
- Period
- 2023
- Total Revenue
- 238.78
- Selling/ General/ Admin Expenses Total
- 412.84
- Depreciation/ Amortization
- 11.77
- Other Operating Expenses Total
- 3.5
- Total Operating Expense
- 462.42
- Operating Income
- -223.64
- Net Income Before Taxes
- -222.58
- Net Income
- -222.58
- Diluted Normalized EPS
- -7.81
- Period
- 2023
- Total Assets
- 830.13
- Total Liabilities
- 317.35
- Total Equity
- 512.78
- Tangible Book Valueper Share Common Eq
- 15.02
- Period
- 2023
- Cashfrom Operating Activities
- -69.12
- Cashfrom Investing Activities
- -548.28
- Cashfrom Financing Activities
- 616.76
- Net Changein Cash
- -0.64
- Period
- 2022
- Total Revenue
- 137.25
- Selling/ General/ Admin Expenses Total
- 290.89
- Depreciation/ Amortization
- 10.16
- Other Operating Expenses Total
- 1.57
- Total Operating Expense
- 333.32
- Operating Income
- -196.07
- Net Income Before Taxes
- -203.4
- Net Income
- -203.4
- Diluted Normalized EPS
- -7.92
- Period
- 2022
- Total Assets
- 280.08
- Total Liabilities
- 248.86
- Total Equity
- 31.23
- Tangible Book Valueper Share Common Eq
- 0.3
- Period
- 2022
- Cashfrom Operating Activities
- -208.23
- Cashfrom Investing Activities
- -29.17
- Cashfrom Financing Activities
- 229.32
- Net Changein Cash
- -8.08
- Period
- 2021
- Total Revenue
- 252.96
- Selling/ General/ Admin Expenses Total
- 347.56
- Depreciation/ Amortization
- 10.92
- Other Operating Expenses Total
- 3.48
- Total Operating Expense
- 398.66
- Operating Income
- -145.7
- Net Income Before Taxes
- -151.14
- Net Income
- -151.14
- Diluted Normalized EPS
- -5.78
- Period
- 2021
- Total Assets
- 229.69
- Total Liabilities
- 397.94
- Total Equity
- -168.25
- Tangible Book Valueper Share Common Eq
- -6.45
- Period
- 2021
- Cashfrom Operating Activities
- -151.9
- Cashfrom Investing Activities
- 1.56
- Cashfrom Financing Activities
- 159.28
- Net Changein Cash
- 8.95
- Period
- 2020
- Total Revenue
- 76.81
- Selling/ General/ Admin Expenses Total
- 323
- Depreciation/ Amortization
- 9.48
- Other Operating Expenses Total
- 2.27
- Total Operating Expense
- 391.77
- Operating Income
- -314.95
- Net Income Before Taxes
- -312.4
- Net Income
- -312.4
- Diluted Normalized EPS
- -11.92
- Period
- 2020
- Total Assets
- 272.56
- Total Liabilities
- 291.2
- Total Equity
- -18.64
- Tangible Book Valueper Share Common Eq
- -1.83
- Period
- 2020
- Cashfrom Operating Activities
- -210.81
- Cashfrom Investing Activities
- 155.35
- Cashfrom Financing Activities
- 55.46
- Net Changein Cash
- 0
- Period
- 2019
- Total Revenue
- 182.87
- Selling/ General/ Admin Expenses Total
- 303.66
- Depreciation/ Amortization
- 7.55
- Other Operating Expenses Total
- 2.07
- Total Operating Expense
- 334.99
- Operating Income
- -152.12
- Net Income Before Taxes
- -145.43
- Net Income
- -145.43
- Diluted Normalized EPS
- -5.61
- Period
- 2019
- Total Assets
- 398.48
- Total Liabilities
- 102.24
- Total Equity
- 296.24
- Tangible Book Valueper Share Common Eq
- 11.28
- Period
- 2019
- Cashfrom Operating Activities
- -171.91
- Cashfrom Investing Activities
- -102.19
- Cashfrom Financing Activities
- 274.25
- Net Changein Cash
- 0.15
- Period
- 2018
- Total Revenue
- 78.26
- Selling/ General/ Admin Expenses Total
- 283.03
- Depreciation/ Amortization
- 8.18
- Other Operating Expenses Total
- 2.03
- Total Operating Expense
- 329.03
- Operating Income
- -250.77
- Net Income Before Taxes
- -197
- Net Income
- -197
- Diluted Normalized EPS
- -9.91
- Period
- 2018
- Total Assets
- 308.81
- Total Liabilities
- 124.09
- Total Equity
- 184.72
- Tangible Book Valueper Share Common Eq
- 7.35
- Period
- 2018
- Cashfrom Operating Activities
- -182.77
- Cashfrom Investing Activities
- -104.62
- Cashfrom Financing Activities
- 224.02
- Net Changein Cash
- -63.38
- Period
- 2024-03-31
- Total Revenue
- 16.56
- Selling/ General/ Admin Expenses Total
- 101.89
- Depreciation/ Amortization
- 3.07
- Other Operating Expenses Total
- 13.04
- Total Operating Expense
- 125.46
- Operating Income
- -108.9
- Net Income Before Taxes
- -105.41
- Net Income
- -105.79
- Diluted Normalized EPS
- -3.26
- Period
- 2024-03-31
- Total Assets
- 515.04
- Total Liabilities
- 389.29
- Total Equity
- 125.75
- Tangible Book Valueper Share Common Eq
- 2.56
- Period
- 2024-03-31
- Cashfrom Operating Activities
- -429.2
- Cashfrom Investing Activities
- 391.53
- Cashfrom Financing Activities
- 42.42
- Net Changein Cash
- 4.75
- Period
- 2023-12-31
- Total Revenue
- 13.86
- Selling/ General/ Admin Expenses Total
- 93.51
- Depreciation/ Amortization
- 3.16
- Other Operating Expenses Total
- 13.94
- Total Operating Expense
- 119.64
- Operating Income
- -105.78
- Net Income Before Taxes
- -99.65
- Net Income
- -99.65
- Diluted Normalized EPS
- -3.07
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 21.18
- Selling/ General/ Admin Expenses Total
- 90.8
- Depreciation/ Amortization
- 3.18
- Other Operating Expenses Total
- 15.38
- Total Operating Expense
- 115.83
- Operating Income
- -94.65
- Net Income Before Taxes
- -86.42
- Net Income
- -86.42
- Diluted Normalized EPS
- -2.66
- Period
- 2023-09-30
- Total Assets
- 667.41
- Total Liabilities
- 335.73
- Total Equity
- 331.68
- Tangible Book Valueper Share Common Eq
- 9.44
- Period
- 2023-09-30
- Cashfrom Operating Activities
- -193.03
- Cashfrom Investing Activities
- 195.45
- Cashfrom Financing Activities
- -1.69
- Net Changein Cash
- 0.73
- Period
- 2023-06-30
- Total Revenue
- 23.95
- Selling/ General/ Admin Expenses Total
- 109.45
- Depreciation/ Amortization
- 3.1
- Other Operating Expenses Total
- 11.51
- Total Operating Expense
- 129.23
- Operating Income
- -105.28
- Net Income Before Taxes
- -95.35
- Net Income
- -95.35
- Diluted Normalized EPS
- -2.94
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 47.69
- Selling/ General/ Admin Expenses Total
- 122.06
- Depreciation/ Amortization
- 2.94
- Other Operating Expenses Total
- 9.41
- Total Operating Expense
- 140.2
- Operating Income
- -92.51
- Net Income Before Taxes
- -81.99
- Net Income
- -81.99
- Diluted Normalized EPS
- -2.55
- Period
- 2023-03-31
- Total Assets
- 830.13
- Total Liabilities
- 317.35
- Total Equity
- 512.78
- Tangible Book Valueper Share Common Eq
- 15.02
- Period
- 2023-03-31
- Cashfrom Operating Activities
- -69.12
- Cashfrom Investing Activities
- -548.28
- Cashfrom Financing Activities
- 616.76
- Net Changein Cash
- -0.64
- Period
- 2022-12-31
- Total Revenue
- 131.09
- Selling/ General/ Admin Expenses Total
- 99.16
- Depreciation/ Amortization
- 3.13
- Other Operating Expenses Total
- 10.7
- Total Operating Expense
- 118.04
- Operating Income
- 13.05
- Net Income Before Taxes
- 10.15
- Net Income
- 10.15
- Diluted Normalized EPS
- 0.35
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Sun Pharma Advanced Research Com Technical
Moving Average
SMA
- 5 Day241.79
- 10 Day239.84
- 20 Day230.91
- 50 Day251.16
- 100 Day310.67
- 300 Day291.74
Sun Pharma Advanced Research Com Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- BLS International Services
- 370.15
- -9.35
- -2.46
- 430
- 201.5
- 15225.63
- Quess Corp
- 642.4
- 5.95
- 0.93
- 670.5
- 397.9
- 9540.24
- Sun Pharma Advanced Research Com
- 243.05
- 2.9
- 1.21
- 474
- 196.45
- 7887.5
- Magellanic Cloud
- 621
- 1.8
- 0.29
- 672.05
- 226.1
- 7258.19
- Allcargo Logistics
- 64.3
- 2.39
- 3.86
- 97.7
- 59.4
- 6319.29
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- BLS International Services
- 49.11
- 12.71
- 23.85
- 14.01
- Quess Corp
- 31.49
- 3.4
- 3.76
- 0.7
- Sun Pharma Advanced Research Com
- -
- 60.67
- -224.74
- -163.4
- Magellanic Cloud
- 69.95
- 17.69
- 30.16
- 13.21
- Allcargo Logistics
- 56.45
- 2.41
- 15.48
- 2.86
Sun Pharma Advanced Research Com Shareholding
Shareholding Pattern
*Promoter pledging: 1.82%
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 24-May-24
- Audited Results
- 05-Feb-24
- Quarterly Results
- 06-Nov-23
- Quarterly Results
- 07-Aug-23
- Quarterly Results
- 22-May-23
- Audited Results & Others
- 13-Feb-23
- Quarterly Results
- 07-Nov-22
- Quarterly Results
- 08-Aug-22
- Quarterly Results & Others
- 17-May-22
- Audited Results
- 04-Feb-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 07-Aug-23
- 22-May-23
- AGM
- 22-Sept-22
- 08-Aug-22
- AGM
- 08-Jun-21
- 12-May-21
- EGM
- 26-Apr-21
- 01-Apr-21
- EGM
![No data](https://www.livemint.com/lm-img/dev/null-data.png)
![No data](https://www.livemint.com/lm-img/dev/null-data.png)
![No data](https://www.livemint.com/lm-img/dev/null-data.png)
![No data](https://www.livemint.com/lm-img/dev/null-data.png)